Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Omission of Venetoclax Ramp-up Dosing during Induction Therapy for Acute Myeloid Leukemia in Combination with DNA Hypomethylating Agents Is Safe and Well-Tolerated

Brian Parkin, Caralyn Escobar, Roma Patel, Tori Smith, Amy Browning, Philip A. Pancari, Arlene A. Gayle, Shahram Mori

Blood (2024) 144 (Supplement 1): 4241.

https://doi.org/10.1182/blood-2024-210960

Published: 2024

Journal Articles

Clinical Utility of Multiple-Gene Mutation Testing By Next-Generation Sequencing in Acute Myeloid Leukemia in Community Hospital Setting

Jingxin Sun, MD PhD, Luwei Tao, MD PhD, Rushang D. Patel, MD PhD, Shahram Mori, MD PhD, Jeff Chang, MD PhD

Blood (2018) 132 (Supplement 1): 4004.

https://doi.org/10.1182/blood-2018-99-119427

Published: 2018

Journal Articles

Addition of Cladribine: Improving Standard of Care in Newly Diagnosed Acute Myeloid Leukemia

Shahram Mori, MD PhD, Nahir Rivera, PharmD BCOP, Mohammed Wazir, MD, Rushang D. Patel, MD PhD, Juan Carlos Varela, MD PhD, Xiang Zhu, MAS, Jason Balls, PAC, Tori Smith, ARNP, Steven C. Goldstein, MD

Blood (2018) 132 (Supplement 1): 3988.

https://doi.org/10.1182/blood-2018-99-120285

Published: 2018

Journal Articles

Acute Promyelocytic Leukemia with FLT3/ITD and RUNX1 Mutation Presenting As Extramedullary Soft Tissue Mass

Shahram Mori, MD PhD, Cai Yuan, MD, Wesam B. Ahmed, MD PhD, Rushang D. Patel, MD PhD

Blood (2016) 128 (22): 5185.

https://doi.org/10.1182/blood.V128.22.5185.5185

Published: 2016

Journal Articles

Low Dose Steroids Can Alleviate Blinatumomab-Associated Toxicities without Negatively Impacting Treatment Efficacy

Shahram Mori, MD PhD, Rebecca Jean Nelson, PharmD, Rushang D. Patel, MDPhD, Wesam B. Ahmed, MD PhD

Blood (2015) 126 (23): 4875.

https://doi.org/10.1182/blood.V126.23.4875.4875

Published: 2015

Journal Articles

Thymoglobulin Does Not Impact Relapse or Survival after Matched Unrelated Transplantation for AML/MDS Compared to Matched Related Donor Transplantation without Thymoglobulin Use

Yasser Khaled, MD, Rushang D. Patel, MDPhD, Shahram Mori, MD PhD, Wesam B. Ahmed, MD PhD, Melhem Solh, MD

Blood (2015) 126 (23): 5477.

https://doi.org/10.1182/blood.V126.23.5477.5477

Published: 2015

Journal Articles

Augmentation of Post-Transplant Immunity: Antigen Encounter at Time of Hematopoietic Stem Cell Transplantation Enhances Antigen-Specific Donor T Cell Responses in the Post-Transplant Repertoire.

Craig A. Mullen, MD PhD, Ulker Kocak, MD, Joanne L. Shaw, BS, Shahram Mori, PhD

Blood (2004) 104 (11): 2246.

https://doi.org/10.1182/blood.V104.11.2246.2246

Published: 2004

NARROW

Omission of Venetoclax Ramp-up Dosing during Induction Therapy for Acute Myeloid Leukemia in Combination with DNA Hypomethylating Agents Is Safe and Well-Tolerated

Clinical Utility of Multiple-Gene Mutation Testing By Next-Generation Sequencing in Acute Myeloid Leukemia in Community Hospital Setting

Addition of Cladribine: Improving Standard of Care in Newly Diagnosed Acute Myeloid Leukemia

Acute Promyelocytic Leukemia with FLT3/ITD and RUNX1 Mutation Presenting As Extramedullary Soft Tissue Mass

Low Dose Steroids Can Alleviate Blinatumomab-Associated Toxicities without Negatively Impacting Treatment Efficacy

Thymoglobulin Does Not Impact Relapse or Survival after Matched Unrelated Transplantation for AML/MDS Compared to Matched Related Donor Transplantation without Thymoglobulin Use

Augmentation of Post-Transplant Immunity: Antigen Encounter at Time of Hematopoietic Stem Cell Transplantation Enhances Antigen-Specific Donor T Cell Responses in the Post-Transplant Repertoire.

Email alerts

ASH Publications

American Society of Hematology

Omission of Venetoclax Ramp-up Dosing during Induction Therapy for Acute Myeloid Leukemia in Combination with DNA Hypomethylating Agents Is Safe and Well-Tolerated

Clinical Utility of Multiple-Gene Mutation Testing By Next-Generation Sequencing in Acute Myeloid Leukemia in Community Hospital Setting

Addition of Cladribine: Improving Standard of Care in Newly Diagnosed Acute Myeloid Leukemia

Acute Promyelocytic Leukemia with FLT3/ITD and RUNX1 Mutation Presenting As Extramedullary Soft Tissue Mass

Low Dose Steroids Can Alleviate Blinatumomab-Associated Toxicities without Negatively Impacting Treatment Efficacy

Thymoglobulin Does Not Impact Relapse or Survival after Matched Unrelated Transplantation for AML/MDS Compared to Matched Related Donor Transplantation without Thymoglobulin Use

Augmentation of Post-Transplant Immunity: Antigen Encounter at Time of Hematopoietic Stem Cell Transplantation Enhances Antigen-Specific Donor T Cell Responses in the Post-Transplant Repertoire.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only